Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)

被引:4
作者
Weinstein, Cindy L. J. [1 ]
Sliwinska-Stanczyk, Paula [2 ]
Hala, Tomas [3 ]
Stanislav, Marina [4 ]
Tzontcheva, Anjela [5 ]
Yao, Ruji [1 ]
Berd, Yuliya [1 ]
Curtis, Sean P. [1 ]
Philip, George [1 ]
机构
[1] Merck & Co Inc, Rahway, NJ USA
[2] Reumat Ctr Reumatol, Warsaw, Poland
[3] CCR Czech As, Pardubice, Czech Republic
[4] Vladimirsky Moscow Reg Sci Inst, Moscow, Russia
[5] MSD, Zurich, Switzerland
关键词
golimumab; non-radiographic axial spondyloarthritis; withdrawal; reduced dosing; efficacy; safety;
D O I
10.1093/rheumatology/kead112
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in. Methods Eligible participants received OL GLM in period 1. In period 2, participants who achieved inactive disease were randomized 1:1:1 to receive double-blind (DB) treatment with monthly placebo (PBO, treatment withdrawal) or continued GLM treatment given monthly (GLM QMT) or every 2 months (GLM Q2MT). Participants who did not have a disease flare continued DB treatment for similar to 12 months. Participants with a disease flare discontinued DB treatment and resumed monthly OL GLM. Primary endpoint compared the proportion of participants without a disease flare in the continued GLM treatment groups (QMT or Q2MT) vs PBO in a multiplicity-controlled, step-down fashion. Safety follow-up continued for similar to 3 months after last treatment. Results A total of 188 patients, out of the 323 enrolled, were eligible for participation in period 2. Both GLM QMT and GLM Q2MT were superior to treatment withdrawal (PBO) in preventing disease flare (P < 0.001), with a treatment-difference vs PBO of 50.4% and 34.4% for the GLM QMT and GLM Q2MT groups, respectively. The time-to-first flare was significantly longer (log-rank P < 0.0001) with GLM treatment compared with PBO. Of 53 participants (in Q2MT or PBO) who had a confirmed disease flare, 51 (96.2%) attained a clinical response within 3 months of restarting OL GLM. Adverse events were consistent with the known GLM safety profile. Conclusion Among participants with active nr-axSpA who attained inactive disease after 10 months of GLM treatment, continued GLM treatment is well tolerated and provides superior protection against disease flares compared with GLM withdrawal. (EudraCT: 2015-004020-65, registered on 30 March 2022; NCT: 03253796, registered on 18 August 2017.)
引用
收藏
页码:3601 / 3609
页数:9
相关论文
共 50 条
[41]   The validity and reliability of quality of life questionnaires in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and meta-analysis [J].
Qian He ;
Jing Luo ;
Jiaqi Chen ;
Jianying Yang ;
Chuanhui Yao ;
Caiqin Xu ;
Qingwen Tao .
Health and Quality of Life Outcomes, 20
[42]   Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT [J].
Jürgen Braun ;
Ricardo Blanco ;
Helena Marzo-Ortega ;
Lianne S. Gensler ;
Filip van den Bosch ;
Stephen Hall ;
Hideto Kameda ;
Denis Poddubnyy ;
Marleen van de Sande ;
Anna S. Wiksten ;
Brian O. Porter ;
Abhijit Shete ;
Hanno B. Richards ;
Sibylle Haemmerle ;
Atul Deodhar .
Arthritis Research & Therapy, 23
[43]   Knowledge, Attitudes, and Practices of Moroccan Community Rheumatologists' Regarding the Management of Non-radiographic Axial Spondyloarthritis: A National Cross-Sectional Study [J].
Kronbi, Fatine ;
Rkain, Hanan ;
Benzine, Nada ;
Ez-zaoui, Samya ;
Abouqal, Radouane ;
Belayachi, Jihane ;
Hajjaj-Hassouni, Najia ;
Tahiri, Latifa ;
Allali, Fadoua .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
[44]   Cross-walk of the Assessment of Spondyloarthritis International Society Health Index and Ankylosing Spondylitis Quality of Life Scores in Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis Patients [J].
Pike, James ;
Dong, Yan ;
Piercy, James ;
Booth, Nicola ;
Holdsworth, Elizabeth ;
Hunter, Theresa .
RHEUMATOLOGY AND THERAPY, 2021, 8 (02) :849-862
[45]   Cross-walk of the Assessment of Spondyloarthritis International Society Health Index and Ankylosing Spondylitis Quality of Life Scores in Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis Patients [J].
James Pike ;
Yan Dong ;
James Piercy ;
Nicola Booth ;
Elizabeth Holdsworth ;
Theresa Hunter .
Rheumatology and Therapy, 2021, 8 :849-862
[46]   A single center experience: physician related diagnostic delay and demographic and clinical differences between patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis [J].
Ulutas, Firdevs ;
Cobankara, Veli ;
Senol, Hande ;
Karasu, Ugur ;
Kaymaz, Serdar ;
Yasar, Canan Albayrak ;
Ok, Zeynep Dundar ;
Yigit, Murat .
ROMANIAN JOURNAL OF INTERNAL MEDICINE, 2021, 59 (03) :278-285
[47]   Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks [J].
Deodhar, Atul ;
Mease, Philip ;
Marzo-Ortega, Helena ;
Hunter, Theresa ;
Sandoval, David ;
Kronbergs, Andris ;
Lauzon, Steven ;
Leung, Ann ;
Navarro-Compan, Victoria .
BMC RHEUMATOLOGY, 2021, 5 (01)
[48]   Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks [J].
Atul Deodhar ;
Philip Mease ;
Helena Marzo-Ortega ;
Theresa Hunter ;
David Sandoval ;
Andris Kronbergs ;
Steven Lauzon ;
Ann Leung ;
Victoria Navarro-Compán .
BMC Rheumatology, 5
[49]   Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis Had Similar TNFi Drug Survival: HUR-BIO Real Life Results [J].
Kalyoncu, Umut ;
Karadag, Omer ;
Kilic, Levent ;
Bilgen, Sule Apras ;
Erden, Abdulsamet ;
Akdogan, Ali ;
Kiraz, Sedat ;
Ertenli, Ihsan .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) :S66-S66
[50]   Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study [J].
van den Bosch, Filip ;
Deodhar, Atul ;
Poddubnyy, Denis ;
Maksymowych, Walter P. ;
van der Heijde, Desiree ;
Kim, Tae-Hwan ;
Kishimoto, Mitsumasa ;
Baraliakos, Xenofon ;
Bu, Xianwei ;
Lagunes-Galindo, Ivan ;
Song, In-Ho ;
Wung, Peter ;
Kato, Koji ;
Shmagel, Anna .
ARTHRITIS RESEARCH & THERAPY, 2025, 27 (01)